Purple Biotech Ltd., an Israeli oncology-focused biotech, reported significant operational challenges in 2025 marked by a $20.5 million impairment loss relating to its CM24 and NT219 therapeutic programs alongside leadership transitions. Despite this, the company demonstrated promising clinical progress with positive Phase 2 data for CM24 and biomarker validation for NT219. The reduction in R&D expenses following trial completions contrasts sharply with heightened operating losses driven by impairment charges. Financing efforts in late 2024 and 2025 through equity offerings have maintained liquidity, leaving Purple Biotech debt-free but reliant on external capital to sustain pipeline development. Monitoring upcoming clinical milestones and strategic execution under new leadership will be critical for the company’s growth and capital management outlook.